People · Operator
Named in public records as an officer, director or promoter · active 2020–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| VelosBio Inc. | — | Biotechnology | Series D+ | $210.5M | $5.6B | 2020 |
| Aura Biosciences, Inc. | — | Biotechnology | Series C | $198.2M | $2.5B | 2021 |
Karan Takhar at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Karan Takhar on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 2 | 35 |
| Peter B. Finn | 1 | 11 |
| Scott L. Glenn | 1 | 9 |
| Cam Gallagher | 1 | 7 |
| Alan Colowick | 1 | 7 |
| MIN CUI | 1 | 5 |
| Casper Breum | 1 | 5 |
| Lawrence C. Best | 1 | 4 |
| Mark Chin | 1 | 4 |
| Javier Garcia | 1 | 3 |
| Pedro Granadillo | 1 | 3 |
| Jayson Punwani | 1 | 3 |
| Art Pappas | 1 | 3 |
| Alan Walts | 1 | 3 |
| Peter Wirth | 1 | 3 |
| Edmundo Muniz, M.D., Ph.D. | 1 | 2 |
| Langdon Miller | 1 | 2 |
| Henri E. Termeer | 1 | 2 |
| Casper E. Breum | 1 | 2 |
| Richard Vincent | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.